Invitation to Collaborate on innovation in Biologics and Bioprocessing – Following yesterday’s announcement by the UK Government to invest an additional ֲ£146m into medicines research, it is clear there has never been a more exciting time for companies to secure funding to de-risk innovative therapies and technologies. However, for a business, it can be difficult to know where to start, and the wealth of information available can be difficult to digest.
The Centre for Process Innovation’s (CPI) National Biologics Manufacturing Centre, based at central park in Darlington, was established to support the growth of the UK biologics industry. The Centre combines state-of-the-art facilities and technical expertise to help companies develop, prove and commercialise the next-generation of biologics. CPI is supporting the commercialisation of research by promoting collaboration with industry across the supply chain, from research through to manufacture and clinic. The Centre is helping companies to commercialise ideas, getting them to market faster with minimal risk, enabling the delivery of innovative manufacturing solutions to accelerate the growth of new and emerging biologic medicines.
Currently CPI is actively looking to collaborate with and support businesses interested in applying for funding to support innovation in biologics and bioprocessing. CPI’s National Biologics Manufacturing Centre has much to offer and we invite potential collaborators to submit project proposals across several areas as follows.
Accessing Cutting Edge Infrastructure and Technical Expertise
CPI has a proven track record of securing and delivering collaborative projects, and can help with all aspects of the development process including selecting the most appropriate call, writing your application, restrictions and regulations right through to delivery and follow on projects. As part of the High Value Manufacturing Catapult, we have a core remit to drive manufacturing technology innovation to benefit UK business and drive UK competitiveness.
CPI has over ֲ£100m of open access development and prototyping facilities. We have helped over 1,000 companies to develop new products and processes and completed over 800 projects worth over ֲ£400m. Within the National Biologics Manufacturing Centre, CPI has secured and is executing 54 projects (completed or in progress), with a total combined value of approximately ֲ£35m for commercial and collaborative projects.
Current Immediate Funding Opportunities
The Biomedical Catalyst aims to develop innovative solutions to health and care challenges. Areas of interest include stratified healthcare (both therapy and diagnostic components), regenerative medicine, diagnostics and enabling medical technologies and devices. Projects can range from 1-3 years in duration, and could be worth ֲ£250k-ֲ£4m.
The Medicines Manufacturing Challenge is the first ֲ£15m investment from a total investment of ֲ£146m into healthcare challenges, and aims to improve the manufacture of novel medicines. Areas of interest include ATMPs, natural product medicines, nucleic acid-based drugs, prophylactic vaccines, protein/peptide biopharmaceuticals, small molecule pharmaceuticals, and virus/phage therapeutics. Projects can be up to 3 years in duration, and could be worth up to ֲ£2m.
If you would be interested in hearing more about the opportunities that are listed above or have a project in mind that could benefit from our collaboration, please contact Mark Bustard, Business Development Director, Biologics, CPI.
